Get startedLog in
    Picture of Thor Medical ASA logo

    TRMED — Thor Medical ASA News Story

    0.000.00%
    no flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Nordic Nanovector's Betalutin Receives Positive Opinion For Orphan Drug Designation From EMA For Marginal Zone Lymphoma

    Picture of Thor Medical ASA logoThor Medical ASA
    14/05/2020 16:47
    May 14 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR'S BETALUTIN® RECEIVES POSITIVE OPINION
FOR
ORPHAN DRUG DESIGNATION FROM EMA FOR MARGINAL ZONE LYMPHOMA
(MZL)

Source text for Eikon:  ID:nWkr3sNhCP 
Further company coverage:  NANOV.OL 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Thor Medical ASA

    See all news